Singapore eDevelopment (SeD)

In Issue 951 (Sept 21), check out insider trades at Singapore eDevelopment and AGV.

The research and testing phase are targeted to be completed early in the fourth quarter of 2020.

Shares in Singapore eDevelopment (SeD) surged as high as 79% to 10 cents following its announcement of its in-vitro success against Covid-19 with its biotechnologies.

Singapore eDevelopment’s (SeD) wholly-owned subsidiary Impact Biomedical says that its Covid-19 research with Global Research and Discovery Group Sciences (GRDG) was published in the peer-reviewed scientific journal Molecules on June 11.

Impact Biomedical’s ownership in the suite is estimated to be at $1.32 billion.

SINGAPORE (Sept 16): Singapore eDevelopment announced wholly-owned subsidiary, HWH World, has entered into a binding term sheet with Todos Medical for the exclusive marketing rights over two breast cancer screening tests – TM-B1 and TM-B2.

SINGAPORE (Feb 28): Singapore eDevelopment (SeD) announced Wednesday that its biomedical subsidiary, Global BioLife Inc., has completed the Zaire Ebola virus research portion for the study of a new anti-viral drug called LB2.

SINGAPORE (Oct 24): Singapore eDevelopment says its US biomedical subsidiary has developed a breakthrough low-calorie, low glycemic index, natural, modified sugar Laetose.

SINGAPORE (May 22): Singapore eDevelopment (SeD), through its subsidiary, Global BioLife Inc., has initiated research on a new universal therapeutic drug platform, known as Linebacker, to combat a range of diseases including Alzheimer’s, diabetes and ca

SINGAPORE (Dec 12): Singapore eDevelopment (SeD) on Monday said it is planning to diversify into the biomedical business.